Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Insulin degludec in a flexible...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes
Bibliographic Details
Main Authors:
Birkeland, K
,
Raz, I
,
Gough, S
,
Atkin, S
,
Shestakova, M
,
Blonde, L
,
Meneghini, L
,
Begtrup, K
,
Johansen, T
,
Bain, S
Format:
Conference item
Published:
2011
Holdings
Description
Similar Items
Staff View
Similar Items
Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes
by: Atkin, S, et al.
Published: (2011)
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
by: Meneghini, L, et al.
Published: (2013)
Type 2 Diabetics, insulin degludec administered once/daily according to a flexible schema assured glycemic control similar to a daily administration according to a fixed hour schema without augmenting hypoglycemic episods
by: Raccah, D, et al.
Published: (2012)
Efficacy and tolerance of insulin degludec administered once/day in a pattern unique flexible compared to insulin glargine once daily at a fixed time in patients with type 2 diabetes (T2D)
by: Huet, D, et al.
Published: (2012)
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015-12-01)